<i>APOE-ε4</i> Carrier Status and Gut Microbiota Dysbiosis in Patients With Alzheimer DiseaseOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study explored whether Alzheimer disease risk genes shape gut bacteria that differ between patients and healthy elders. Researchers combined genotyping with stool microbiome profiling in a case-control design. Twelve reported Alzheimer risk variants, including APOE, were genotyped from blood. Gut bacteria were characterized by 16S rRNA V3-V4 sequencing. Multivariate linear modeling (MaAsLin) tested associations between specific taxa and the genetic variants, adjusting for age and sex.
Who was studied?
Participants were older adults from Xinjin, Chengdu, China, aged 60 to 80 years. The genetic analysis covered 30 Alzheimer patients and 47 cognitively healthy controls, matched on age and sex. Stool sequencing succeeded for 61 samples: 21 patients and 40 controls. Diagnosis followed standard Alzheimer criteria assessed by a multidisciplinary team. Groups were similar in body mass index, cholesterol, and glucose. People with gastrointestinal disease, recent antibiotics, or probiotic use were excluded.
What were the most important findings?
Proteobacteria was more abundant in Alzheimer patients (24 percent) than controls (12 percent), while Firmicutes and Bacteroidetes were slightly lower. Alpha diversity did not differ significantly. LEfSe flagged 18 altered taxa. Proteobacteria, Enterobacteriaceae, and Desulfovibrionaceae rose in patients, while several short-chain fatty acid producing genera, including Megamonas, declined. The APOE epsilon-4 allele and the BIN1 variant rs744373 raised Alzheimer risk. Epsilon-4 was independently associated with higher Proteobacteria (FDR p equals 0.029) and Enterococcaceae (FDR p equals 0.046).
What are the greatest implications of this study?
The results suggest a host risk gene, APOE epsilon-4, is linked to specific gut bacteria independent of disease status. This connects genetics and the microbiome in Alzheimer disease. Expansion of Proteobacteria pathogens and loss of short-chain fatty acid producers may contribute to Alzheimer pathology through host metabolism. Modulating these bacteria is proposed as a possible strategy. The sample was small and single-center, and 16S sequencing limits species-level detail. The design cannot establish causation, which requires longitudinal or animal studies.